Status:
COMPLETED
Evaluation of Metamemory in Patients With Schizophrenia
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
LAPSCO, Psychology University, Blaise Pascal University, Clermont-Ferrand.
Conditions:
Schizophrenia
Aging
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the respective roles of aging and schizophrenia in the regulation of metamemory using a generation strategy. 4 groups will be necessary to comparison: Adult ...
Detailed Description
Metamemory measurement * Objective: Measurement of monitoring and control capabilities, and relations between these two abilities when learning of word pairs. * Description: The hardware consists of ...
Eligibility Criteria
Inclusion
- For both:
- Age: between 18 and 45 years for adults, and 59.55 and above for older,
- For patients :
- DSM-5 criteria of schizophrenia
- Adult patients (\<45 years) will be matched to elderly patients (\> 59.55 years) gender and educational level,
- Patients followed as outpatients,
- Age of onset of the disease less than 40 years,
- Patients whose disease has stabilized: no changes psychotropic treatment for at least 1 month
- Not more of a benzodiazepine,
- Patients on protection of justice or not,
- For controls :
- \- Matched for sex to patient
- Age-matched (+/- 3 years) to patient
- Matched for educational level (+/- 2 years) to patients
Exclusion
- -For patients :
- Any other comorbid psychiatric diagnosis of Axis I DSM-5 (particularly depression, addiction excluding tobacco, dementia)
- Patients with impaired vision or hearing preventing the realization of the tests.
- Long-term Anticholinergic treatment.
- Patients with less 5 years of school
- For controls:
- Any psychiatric diagnosis according to DSM-5, including addictions (excluding tobacco)
- Head injuries, brain injuries or diseases,
- vision or hearing problems preventing the realization of the tests.
- Current or past addiction to all toxic substances except tobacco.
- Long-term Anticholinergic treatment.
- Related to the first degree diagnosed with a psychotic disorder
Key Trial Info
Start Date :
February 8 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 23 2016
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03338179
Start Date
February 8 2011
End Date
May 23 2016
Last Update
November 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003